Last reviewed · How we verify

NCT03672877

Randomized Controlled Trial of Early Intensive Leg Exercise to Improve Walking in Children With Diplegia

Recruiting now NA Last updated 27 March 2025
What this trial tests

NA trial testing Intensive exercise in Spastic Diplegia in 60 participants. Currently enrolling.

Timeline
28 January 2019
Primary endpoint
31 March 2026
31 March 2027

Quick facts

Lead sponsorUniversity of Alberta
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date28 January 2019
Primary completion31 March 2026
Estimated completion31 March 2027
Sites2 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

University of Alberta

Who can join

Adults 8 Months to 36 Months, any sex, with Spastic Diplegia or Periventricular Leukomalacia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized controlled trial, comparing 3 months of intensive leg exercise to standard physiotherapy care for the improvement of gross motor function in young children with spastic diplegia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Engaging the Lower Extremity via Active Therapy Early (ELEVATE) Is Feasible and May Improve Gross Motor Function in Children with Spastic Bilateral Cerebral Palsy: A Case Series.
    Hurd CL, Livingstone D, Smith A, Yang JF. · · 2023 · PMID 38037582 · DOI 10.3138/ptc-2023-0005

Verify or expand the search:

Other recruiting trials for Spastic Diplegia

Currently open trials in the same condition.

Other University of Alberta trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03672877.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing